Dr. Mehmet Oz has announced the launch of a federal pilot program that will allow certain Medicare beneficiaries to access hemp-derived CBD products, with coverage expected to begin as early as 2026. The initiative, developed through the Centers for Medicare & Medicaid Services (CMS), marks a significant shift in how cannabinoid-based products are treated within federal healthcare programs.
The program is designed to provide eligible patients—particularly older adults—with access to CBD products at low or no cost when recommended by a physician. Officials say the effort is intended not only to expand access to alternative therapies, but also to gather data on safety, effectiveness, and outcomes across a large patient population.
While the focus is primarily on CBD, some versions of the program may allow products that contain trace amounts of THC, reflecting the reality of how many hemp-derived products are manufactured.
The initiative follows a broader push from the Trump administration to reevaluate cannabis policy, including efforts to reschedule marijuana and expand research into its medical potential. Supporters say the Medicare pilot could improve access for patients dealing with chronic pain, cancer-related symptoms, and other conditions, especially among seniors who may benefit from alternative treatment options.
At the same time, the rollout raises questions about regulation, oversight, and how cannabis-derived products will be integrated into a federally funded healthcare system. As the program develops, it is expected to play a key role in shaping future federal policy on CBD and related compounds.
Dabbin-Dad Newsroom
